Endocrinology

MS305: Increlex™ (mecasermin [rDNA origin] injection) Growth Forum Database – IGFD Registry: A Patient Registry for Monitoring Long-term Safety And Efficacy of Increlex™ (IRB# 29050)

Status: Active

Investigators:

Peter Allen Lee, M.D., Ph.D.

Description:

To obtain long-term safety data for Increlex™ replacement therapy in children with growth failure; To obtain long-term efficacy data for Increlex™ replacement therapy in children with growth failure.

Eligibility:

Children receiving Increlex™ by a qualified practitioner, informed consent.

Additional Study Details:

What is expected of me and my child?

as a part of their routine medical care and for at least one visit after the child stops taking the medicine. Facts include questions about medical history, growth history, height of parent and child, any previous medicine for slow growth, and other current concomitant medicines. Physical exams performed as normal, including height, weight, bone age scan, and pubertal status.. If the child took part in another study before and received Increlex™, this consent allows for the facts from that study to be used for this study also.

Locations:

Penn State Hershey Medical Center, Briarcrest Clinic

Contacts:

Jennifer Stokes, RN, BSN, CCRC
jstokes1@hmc.psu.edu

717-531-5656